• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Afro-Egyptian Journal of Infectious and Endemic Diseases
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 15 (2025)
Volume Volume 14 (2024)
Volume Volume 13 (2023)
Volume Volume 12 (2022)
Volume Volume 11 (2021)
Volume Volume 10 (2020)
Volume Volume 9 (2019)
Volume Volume 8 (2018)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 7 (2017)
Volume Volume 6 (2016)
Volume Volume 5 (2015)
Volume Volume 4 (2014)
Volume Volume 3 (2013)
Volume Volume 2 (2012)
Volume Volume 1 (2011)
Fathallah, M., Elhamouly, M., Moustafa, A., Gaber, A. (2018). Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients. Afro-Egyptian Journal of Infectious and Endemic Diseases, 8(4), 209-217. doi: 10.21608/aeji.2018.23078
Mohamed Fathallah; Mohammed Elhamouly; Amany Moustafa; Ahmed Gaber. "Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients". Afro-Egyptian Journal of Infectious and Endemic Diseases, 8, 4, 2018, 209-217. doi: 10.21608/aeji.2018.23078
Fathallah, M., Elhamouly, M., Moustafa, A., Gaber, A. (2018). 'Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients', Afro-Egyptian Journal of Infectious and Endemic Diseases, 8(4), pp. 209-217. doi: 10.21608/aeji.2018.23078
Fathallah, M., Elhamouly, M., Moustafa, A., Gaber, A. Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2018; 8(4): 209-217. doi: 10.21608/aeji.2018.23078

Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients

Article 8, Volume 8, Issue 4, December 2018, Page 209-217  XML PDF (427.09 K)
Document Type: Original Article
DOI: 10.21608/aeji.2018.23078
View on SCiNiTO View on SCiNiTO
Authors
Mohamed Fathallah email 1; Mohammed Elhamouly1; Amany Moustafa2; Ahmed Gaber1
1Department of Endemic and Infectious Diseases, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
2Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Abstract
Background and study aim: Recently, multiple regimens of different direct-acting antiviral agents (DAAs) have been emerged. We aimed to assess the efficacy, safety and improvement of liver profile for patients treated with regimens of direct acting-antivirals in Egypt.
Patients and Methods: A retrospective observational study was conducted at Suez governorate, including a simple random sample of 76 patients treated with directly-acting antiviral therapy and came to our center to enroll our follow up program after antiviral therapy from November 2015 to May 2016. Sustained viral response (SVR) was established at week 12 after end of treatment.
Results: A total of 76 chronic hepatitis C patients initiated treatment with DAAs. Forty patients (52.6%) were treated with triple therapy and thirty-six patients (47.3%) with dual therapy. All patients were treated for 12 weeks. According to Intention to treat analysis, 35 of 40 patients (87%) who treated with triple therapy achieved SVR while 32 of 36 patients (88.9%) treated with dual therapy achieved SVR. However, the difference between responders after both regimens wasn’t statistically significant (p= 1). In the group treated with triple therapy, significantly more patients had anemia, leukopenia and thrombocytopenia with no serious side effects leading to discontinuation of therapy.
Conclusion: Both regimens had similar efficacy, but the dual therapy was more tolerated with less side effect profile.
Keywords
Sofosbuvir; simeprevir; HCV RNA; interferon
Main Subjects
Endemic medicine; Hepatology; Infectious diseases
Statistics
Article View: 310
PDF Download: 549
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.